
|Articles|August 1, 2003
Bevacizumab Results Favorable But Not Definitive
Author(s)John Otrompke
Chicago - A phase II trial of a new recombinant agent in the fight against melanoma has accrued 28 patients so far, yielding interesting data but so far no conclusive results, according to an abstract presented at this year's annual meeting of the American Society of Clinical Oncology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Dual-Action Microneedle Patch Shows Promise for Psoriasis in Preclinical Study
3
AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation
4
Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial
5














